# Synthesis, Crystal Structure and Biological Activity of 1-(4-(4-Ethoxybenzyl)piperazin-1-yl)-2- (2-methylphenoxy)ethanone

LI Xiao-Feng②) (李小凤);CHEN Xiao-Hong②(陈晓宏);ZHONG Yan①(仲 琰);XU Yi②(许 逸);LIPing(3)(李 萍);WUBin(②(吴 斌)

(1) Schoolof Chemistry and Chemical Engineering, Southeast University, Nanjing 211189,China;(2 Schoolof Pharmacy, Nanjing Medical University, Nanjing 211166, China;3） School of Basic Medical Sciences,Nanjing Medical University, Nanjing 210029, China

ABSTRACTOne novel phenoxyacetamide derivative ( $\mathrm { \ C } _ { 2 2 } \mathrm { H } _ { 2 8 } \mathrm { N } _ { 2 } \mathrm { O } _ { 3 }$ ， $M _ { r } = 3 6 8 . 4 7 \$ ）has been synthesized and determined by means of NMR spectroscopy， high resolution mass spectra and single-crystal $\mathrm { \Delta } X$ -ray diffraction. The single crystal belongs to the monoclinic system, space group $C c$ with $a = 1 4 . 9 1 0 ( 3 )$ ， $b =$ 14.592(3), c = 38.683(8) A, $\beta = 1 0 0 . 3 7 ( 3 ) ^ { \circ }$ , V = 8279(3) A3, $Z = 1 6$ $D _ { c } = 1 . 1 8 3 ~ \mathrm { g / c m ^ { 3 } } .$ $F ( 0 0 0 ) = 3 1 6 8$ $\mu =$ $0 . 0 7 9 \ \mathrm { m m ^ { - 1 } }$ ，MoKα radiation $( \lambda = 0 . 7 1 0 7 3 \mathrm { ~ \AA ~ }$ )，the final $R = 0 . 0 5 0 8$ and $w R = 0 . 0 6 6 6$ for 4120 observed reflections with $I > 2 \sigma ( I )$ . There are four independent molecules in an asymmetric unit cell. The four symmetry-independent molecules have a variety of diffrent conformations indicating considerable conformational freedom.The bioassay results indicated that the title compound displayed efective activities against glutamine-induced neurotoxicity in PC12 cels and significantly prolonged the survival time of mice subjected to acute cerebral ischemia.

Keywords: phenoxyacetamide; crystal structure;synthesis; anti-ischemic activity; DOI: 10.14102/j.cnki.0254-5861.2011-1710

# 1 INTRODUCTION

Acute ischemic stroke (AIS) is a disease that is characterized by neuronal dysfunction and apoptosis induced by the iterruption of blood supply resulting from the occlusion or rupture of blood vessels[1,2l. It is the most common cause of death and a major cause of disability worldwidel3,4l. In China, the costs associated with the treatment for ischemic stroke are a large financial burden.

The last three decades have witnessed a new surge of basic science investigations on the pathophysiological events folowing AIS. Although so far clinical trials have repeatedly failed, neuroprotection is still a promising option for AIS treatment[5].

Ourprevious studies discovered that phenoxyacetyl diphenylmethylpiperazine analogs often show neuroprotective activity in Glu-induced PC12 celsl6]. Preliminary structure-activity relationship (SAR) study indicated that replacing diphenylmethylpiperazine with benzylpiperazine moiety probably improved the neuroprotective effect. In the present investigation,we prepared a new phenoxyacetyl benzylpiperazine derivative,namely1-(4-(4-ethoxybenzyl)piperazin-1-yl)-2-(2-methylphenoxy)ethanone (Scheme1)，and detected its crystal structure by X-ray difraction method.The neuroprotection of the title compound was also characterized.

# 2 EXPERIMENTAL

# 2.1 Materials and apparatuses

All chemicals,reagents,and solvents were of analytical grade and used without further purification. Melting point was determined on an electrothermal digital apparatus model WRR-401 (Shanghai, China) without correction. The $\mathrm { ^ { 1 } H }$ and $^ { 1 3 } \mathrm { C }$ NMR spectra were measured on a Bruker ACF-5OO Instrument (Bruker） with CDCl3 as the solvent and TMS as the internal standard (chemical shifts are expressed as $\delta$ values, $J$ in hertz). High resolution mass spectra (HRMS） were recorded on a MALDI Micro MX instrument (Waters). Fetal bovine serum (FBS） was obtained from HyClone (Logan， UT, USA). Horse serum (HS)， penicilin and streptomycin were obtained from Gibco BRL (Div. of Invitrogen，Gaithers-burg，MD，USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT） was purchased from Sigma Chemical Co. (St. Louis, MO, USA).

# 2.2 Synthesis

The title compound was conveniently synthesized as outlined in Scheme 1.The intermediates 2 and 3 were synthesized according to our previous workl6]. The key intermediate 4-ethoxybenzyl bromide 6 was prepared byfree-radical bromination of commercially available 4-ethoxytoluene 5with litle excessof $N$ bromosuccinimide(NBS)l7].Thetitlecompound1-(4-(4-ethoxybenzyl)piperazin-1-yl)-2-(2-metyphenoxy)ethanone 7 was obtained as the following description. Under a nitrogen atmosphere, 2-methylphenoxyacetyl piperazine ( $3 , 1 7 . 0 \ \mathrm { m m o l }$ ),4-ethoxybenzyl bromide( $\mathbf { \delta 6 , 1 7 . 0 \ m m o l }$ ),and triethylamine (2.4 mL,17.0 mmol) in acetonitrile ( $\mathrm { 9 0 ~ m L }$ ）were heated to reflux for $2 0 \mathrm { h }$ . The reaction mixture was filtered and the solvent was removed in vacuo.The crude product was purified by column chromatography on silica gel ( $1 0 0 { \sim } 2 0 0$ mesh) using a mixture of ethyl acetate and petroleum ether (V/V 2:1) as eluent to afford target compound 7 as a white solid, yield $67 . 8 \%$ . m.p.: $7 7 . 3 { \sim } 8 0 . 2 \mathrm { ~ } ^ { \circ } \mathrm { C }$ $\mathrm { ^ { 1 } H }$ NMR (CDCl3, 500 MHz) & $\vdots 7 . 1 9 \sim 7 . 1 3$ (m, 2H, Ar-H), $7 . 1 4 { \sim } 7 . 1 1$ (m, 2H, Ar-H), $6 . 8 9 \sim 6 . 8 1 \$ (m,4H, Ar-H), 4.67 (s, 2H, $\mathrm { O C H _ { 2 } C O } ^ { \cdot } ,$ ,4.03 (q, $J = 7 ~ \mathrm { H z }$ 2H， $\mathrm { P h O C } H _ { 2 } \mathrm { C H } _ { 3 }$ ）， $3 . 6 3 \sim 3 . 6 0$ (m，4H, $\mathrm { C O N } ( \mathrm { C H } _ { 2 } ) _ { 2 } ,$ ），3.43(s，2H， $\mathrm { P h C H } _ { 2 } \mathrm { N } _ { \cdot }$ ， $2 . 4 1 \sim 2 . 3 9$ (m，4H, $\mathrm { P h C H } _ { 2 } \mathrm { N } ( C H _ { 2 } ) _ { 2 } ,$ ,2.23 (s,3H,PhCH3)，1.41 (t, $J = 7 ~ \mathrm { H z }$ 3H, $\mathrm { P h O C H } _ { 2 } C H _ { 3 } \$ ） $^ { 1 3 } \mathrm { C }$ NMR ( $\mathrm { C D C l } _ { 3 }$ ,75 MHz) δ: 16.23,4.24,45.52,51.96,52.62,53.10, 60.23,67.96,11.03,121.27,126.63,126.95,127.19,129.84,129.88, 130.90,131.14,131.48,138.78,155.95,166.56.HRMS (ESI, $m / z$ ): Calcd. for $\mathrm { C _ { 2 2 } H _ { 2 8 } N _ { 2 } O _ { 3 } \left[ M + H \right] ^ { + } 3 6 9 . 2 1 7 8 }$ found 369.2176.

Single crystals of the title compound suitable for $\mathrm { \Delta } X$ -ray diffraction were grown by slow evaporation of acetonitrile at room temperature.

![](images/d65c23b1702f94a8eb14591cb128ec019123e63c532d1ea2ebc4b5e9038e0e4b.jpg)  
Scheme1. Synthesis of the title phenoxyacetamide compound 7

# 2.3X-ray crystal structure determination

A colorless single crystal of the title compound with dimensions of $0 . 3 0 \mathrm { m m } \times 0 . 2 0 \mathrm { m m } \times 0 . 1 0 \mathrm { m m }$ was selected for $\mathbf { \boldsymbol { X } }$ -ray diffraction studies. The data were collected on an Enraf-Nonius CAD4/PC four-circle difractometer equipped with a graphite-monochromatic $\mathbf { M o } K \boldsymbol { a }$ radiation $( \lambda = 0 . 7 1 0 7 3 \mathrm { ~ \AA ~ }$ at 293(2) K using an $\omega / 2 \theta$ scan mode in the range of $1 . 0 7 { \leqslant } \theta { \leqslant } 2 5 . 3 7 ^ { \circ }$ （ $0 \leqslant h \leqslant 1 7$ ， $0 { \leqslant } k { \leqslant } 1 7$ ， $- 4 6 \leqslant l \leqslant 4 5$ ). The structure was solved by direct methods using SHELXS-97 and refined against $F ^ { 2 }$ by full-matrix least-squares method on the positional and anisotropic temperature parameters of non-hydrogen atoms,or equivalently corrsponding to 973 crystallographic parameters, using SHELXL $9 7 ^ { [ 8 ] }$ . All $\mathrm { H }$ atoms were positioned geometrically and treated using a riding model by fixing the bond lengths at $0 . 9 3 \ : \mathrm { C H }$ atoms.A total of 8127 reflections were collected, of which 7919 were independent $( R _ { \mathrm { i n t } } = 0 . 0 7 2 3 )$ ）and 4120 were observed with $I > 2 \sigma ( I )$ . The final refinement gave $R = 0 . 0 5 0 8$ ， $w R = 0 . 0 6 6 6$ $( w = 1 / [ \sigma ^ { 2 } ( F _ { o } ^ { ~ 2 } ) + ( 0 . 0 2 0 0 P ) ^ { 2 } ]$ ，where $P = ( F _ { o } ^ { ~ 2 } + 2 F _ { c } ^ { ~ 2 } ) / 3 )$ ， $S = 1 . 0 0 8$ ， $( \Delta \rho ) _ { \mathrm { { m a x } } } =$ （204号 0.140, $( \Delta \rho ) _ { \mathrm { m i n } } = - 0 . 1 2 0 ~ \mathrm { e } / \mathring { \mathrm { A } } ^ { 3 } .$ （

# 2.4Biological activity

In order to investigate the in vitro neuroprotective activity，the title compound 7 was screened in Glu-induced PC12 cels[9,10l. The cellular viability was assessed by MTT assay[11, 12].

PC12 cels were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with $10 \%$ (v/v) FBS, $5 \%$ (v/v) HS, $1 0 0 ~ \mathrm { U / m L }$ penicillin, and $1 0 0 ~ \mathrm { U / m L }$ streptomycin at $3 7 \ \mathrm { { ^ \circ C } }$ in a humidified atmosphere of $5 \%$ carbon dioxide.

PC12 cells were inoculated in a 96-well microplate ( $1 0 ^ { 5 }$ cells/well in $1 0 0 ~ \mu \mathrm { L }$ medium） for $2 4 \mathrm { ~ h ~ }$ After washing with PBS,the PC12 cels were incubated with Glu (10 mmol/L)or Glu (10 mmol/L) with compound 7 (0.1, 1, $1 0 \ \mathrm { \textmu m o l { } / L }$ ）or Edaravone $( 9 0 ~ \mathrm { \textmu m o l / L } )$ for $2 4 \mathrm { ~ h ~ }$ ,respectively, at which the MTT $( 1 0 ~ \mu \mathrm { L } , 5 ~ \mathrm { m g / m L } )$ （204号 was added to each culture well. After incubation at $3 7 \mathrm { ~ \textdegree C }$ for an additional $^ { 4 \mathrm { ~ h ~ } }$ ,the formazan crystals were dissolved by the addition of $1 5 0 ~ \mu \mathrm { L }$ dimethyl sulfoxide (DMSO),and the plates were shaken vigorously to ensure complete solubilization.Formazan absorbance was assessed at $4 9 0 \mathrm { n m }$ by an ELISA plate reader[9,10].

The in vivoanti-ischemic activity was tested using bilateral commoncarotid arteryocclusion[13,14l Kunming mice of both sexes were randomly divided into groups (10 mice per group). The title compound was dissolved in aqueous $0 . 5 \%$ sodium carboxy methyl cellulose (CMCNa） solution before use and administered intraperitoneally (i.p.). Nimodipine was i.p. treated with $8 0 ~ \mathrm { m g / k g }$ as a positive control. The negative control group received normal saline (NS)in the same volume as other groups. All groups were given drugs twice a day for 3 days. Sixty minutes after the last administration,all mice were anesthetized by ether. All groups underwent the operation for common carotid artery and vagus nerves ligation.Then the survival time of mice was recorded.

# 3 RESULTSANDDISCUSSION

# 3.1Crystal structure of compound 7

The $\mathrm { ^ { 1 } H }$ NMR, $^ { 1 3 } \mathrm { C }$ NMR,H RMS and X-ray difraction data for the product are in good agreement with the structure of the title compound 7,and its molecular structure and packing diagram are shown in Figs.l and 2, respectively.The selected bond distances,bond angles and torsion angles are listed in Table 1,and the corresponding lengths and angles of hydrogen bonds are given in Table 2.

Molecules of 7 crystallize in monoclinic $C c$ space group. There are four independent molecules in the asymmetric unit cell. For our convenience we named these molecules as $A , B , C$ and $D$ . The average bond lengths and bond angles of benzene rings are normal. The $\scriptstyle { \mathrm { C = O } }$ bond distances of all four molecules,

C(14)=0(2) (1.234(5) A), C(36)=0(5) (1.229(5) A), C(58)=0(8) (1.209(5) A) and $\scriptstyle \mathbf { C } ( 8 0 ) = \mathbf { O } ( 1 1 )$ (1.241(5) A), are found almost equal to a typical $\scriptstyle { \mathrm { C = O } }$ double bond (1.20 A)[15]. The distances of N(2)-C(14), N(4)-C(36), N(6)-C(58) and N(8)-C(80) are 1.347(6)，1.326(6)，1.328(6) and 1.349(6) A,respectively.They are remarkably shorter than the typical $\mathbf { C } ( s p ^ { 2 } )$ -N bond $( 1 . 4 2 6 \mathring \mathrm { A } )$ , but closer to the $\mathrm { C = N }$ double bond (1.33 A)[16]

As shown in Fig.1,in the structure of the title compound,the piperazine rings of allfour molecules are in a chair conformation with the $\mathrm { N - C O C H _ { 2 } C O - }$ and N-benzyl groups in the equatorial positions. The $\mathbf { C } ( s p ^ { 2 } ) \mathbf { - } \mathbf { N }$ bonds lie in the planes of the carbonyl groups of all four molecules (N(2)-C(14)-C(15)-O(3) $- 1 7 5 . 8 ( 4 ) ^ { \circ }$ N(4)-C(36)-C(37)-O(6) -171.4(4)°， N(6)-C(58)-C(69)-0(9) -179.3(5)° and N(8)-C(80)-C(81)-0(12) $1 7 8 . 9 ( 4 ) ^ { \circ } )$ . The molecule contains two essentially planar phenyl rings which are not coplanar. In molecule $A$ ， the 4-ethoxyphenyl ring makes a dihedral angle of $5 7 . 7 ( 3 ) ^ { \circ }$ with the 2-methylphenyl ring. In molecule $B$ ，the respective angle is $5 9 . 5 ( 3 ) ^ { \circ }$ ，while values of $6 4 . 6 ( 3 ) ^ { \circ }$ and $6 3 . 6 ( 4 ) ^ { \circ }$ are observed in molecules $C$ and $D$ . The bond angles of the amide groups of molecules $A$ $B$ ， $C$ and $D$ are $1 2 2 . 7 ( 5 ) ^ { \circ }$ ,122.8(5)°, $1 2 3 . 3 ( 5 ) ^ { \circ }$ and $1 2 2 . 0 ( 5 ) ^ { \circ }$ respectively. The torsion angles of O(2)-C(14)-C(15)-O(3), O(5)-C(36)-C(37)-O(6), O(8)-C(58)-C(59)-0(9) and O(11)-C(80)-C(81)-O(12) are equal to $5 . 7 ( 7 ) ^ { \circ } , 6 . 2 ( 7 ) ^ { \circ } , - 0 . 8 ( 7 ) ^ { \circ }$ and $1 . 4 ( 7 ) ^ { \circ }$ ,respectively.

Molecules of 7 show intra- as well as intermolecular hydrogen bonding. Among four molecules of 7, similar ends of pair of molecules $A$ ， $C$ and $B , D$ form dimers via ${ \mathrm { C - H \mathrm { \mathrm { \cdot \cdot } } \mathrm { \cdot \mathrm { O } } } }$ interactions. Piperazine hydrogen (H(11A), H(33A), H(56A) and H(78B)) and phenoxyacetyl group hydrogen (H(15A), H(37A), H(59A) and H(81B)) are involved in ${ \mathrm { C - H \mathrm { \mathrm { \cdot \cdot } } O } }$ interaction. In the crystal, C-H·O hydrogen bonds link the molecules into two crystalographically independent chains,and each chain is formed by two alternating independent molecules. These C-H.O hydrogen bonds and weak $\mathrm { C - H } \cdots \pi$ interactions strengthen the integration of the three-dimensional network.These interactions are estimated to play arole in stabilizing the crystal structure.

<html><body><table><tr><td>Bond</td><td>Dist.</td><td>Bond</td><td>Dist.</td><td>Bond</td><td>Dist.</td></tr><tr><td>0(2)-C(14)</td><td>1.234(5)</td><td>N(2)-C(14)</td><td>1.347(6)</td><td>0(3)-C(15)</td><td>1.405(5)</td></tr><tr><td>0(5)-C(36)</td><td>1.229(5)</td><td>N(4)-C(36)</td><td>1.326(6)</td><td>0(6)-C(37)</td><td>1.427(6)</td></tr><tr><td>0(8)-C(58)</td><td>1.209(5)</td><td>N(6)-C(58)</td><td>1.328(6)</td><td>0(9)-C(59)</td><td>1.404(6)</td></tr><tr><td>0(11)-C(80)</td><td>1.241(5)</td><td>N(8)-C(80)</td><td>1.349(6)</td><td>0(12)-C(81)</td><td>1.449(6)</td></tr><tr><td>Angle</td><td></td><td>Angle</td><td></td><td>Angle</td><td></td></tr><tr><td>0(2)-C(14)-N(2)</td><td>122.7(5)</td><td>0(2)-C(14)-C(15)-0(3)</td><td>5.7(7)</td><td>N(2)-C(14)-C(15)-0(3)</td><td>-175.8(4)</td></tr><tr><td>0(5)-C(36)-N(4)</td><td>122.8(5)</td><td>0(5)-C(36)-C(37)-0(6)</td><td>6.2(7)</td><td>N(4)-C(36)-C(37)-0(6)</td><td>-171.4(8)</td></tr><tr><td>0(8)-C(58)-N(6)</td><td>123.3(5)</td><td>0(8)-C(58)-C(59)-0(9)</td><td>-0.8(7)</td><td>N(6)-C(58)-C(59)-0(9)</td><td>-179.3(5)</td></tr><tr><td>0(11)-C(80)-N(8)</td><td>122.0(5)</td><td>0(11)-C(80)-C(81)-O(12)</td><td>1.4(7)</td><td>N(8)-C(80)-C(81)-O(12)</td><td>178.9(4)</td></tr></table></body></html>

Table 2.Hydrogen Bond Lengths $( \mathring \mathbf { A } )$ and Bond Angles (°)   

<html><body><table><tr><td>D-H·A</td><td>D-H</td><td>HA</td><td>D…A</td><td>D-HA</td></tr><tr><td>C(11)-H(11A).·O(8)i</td><td>0.97</td><td>2.55</td><td>3.341(7)</td><td>139</td></tr><tr><td>C(12)-H(12B)·O(2)</td><td>0.97</td><td>2.34</td><td>2.753(7)</td><td>105</td></tr><tr><td>C(15)-H(15A).·O(8)</td><td>0.97</td><td>2.43</td><td>3.351(6)</td><td>158</td></tr><tr><td>C(22)-H(22A)··O(3)</td><td>0.96</td><td>2.30</td><td>2.740(8)</td><td>107</td></tr><tr><td>C(33)-H(33A)··O(11)</td><td>0.97</td><td>2.48</td><td>3.292(7)</td><td>141</td></tr><tr><td>C(34)-H(34B)·O(5)</td><td>0.97</td><td>2.36</td><td>2.772(8)</td><td>105</td></tr><tr><td>C(37)-H(37A)·O(11)</td><td>0.97</td><td>2.38</td><td>3.319(6)</td><td>162</td></tr><tr><td>C(44)-H(44A)·O(6)</td><td>0.96</td><td>2.23</td><td>2.725(8)</td><td>111</td></tr><tr><td>C(55)-H(55B)..O(8)</td><td>0.97</td><td>2.35</td><td>2.744(8)</td><td>104</td></tr><tr><td>C(56)-H(56A)··O(2)</td><td>0.97</td><td>2.55</td><td>3.365(7)</td><td>142</td></tr><tr><td>C(59)-H(59A).·O(2)i</td><td>0.97</td><td>2.36</td><td>3.253(7)</td><td>153</td></tr><tr><td>C(66)-H(66A).O(9)</td><td>0.96</td><td>2.27</td><td>2.734(7)</td><td>109</td></tr><tr><td>C(77)-H(77A)·O(11)</td><td>0.97</td><td>2.34</td><td>2.760(7)</td><td>106</td></tr><tr><td>C(78)-H(78B).·O(5)i</td><td>0.97</td><td>2.50</td><td>3.327(7)</td><td>144</td></tr><tr><td>C(81)-H(81B)..O(5)i</td><td>0.97</td><td>2.37</td><td>3.231(6)</td><td>148</td></tr><tr><td>C(88)-H(88A)·O(12)</td><td>0.96</td><td>2.31</td><td>2.760(7)</td><td>108</td></tr></table></body></html>

Symmetry codes: (i) $- 1 / 2 + x$ ,3/2-y， $1 / 2 + z ;$ (ii) $x ,$ 2-y, $- 1 / 2 + z$ (ii) $1 / 2 + x , - 1 / 2 + y$ ：

C73 C79 C78 c W C80012 C41c18 010c70 01106 C38 C15 02 C33C43 C37 C42 C16 C14C10N1 C9 C5 C323 34 C19 2C21 C11N2 C1213 C6 C4 C31 05c34 C7 C3 01 C28 C29 C8 C27 C30 C2 C1 C25 C62 Pc61 C66 09 08 1 C58 C55 C54 C50 C26 C49 C4807 C45 04 C24 0 C63 C64C60 C59 N6 N5C53 647 C46 C23 C56 C57

![](images/5e159d264da3857d8ca1ac6b4776e1282619c4541aa73c090e99fa51d2574df2.jpg)  
Fig.2. Packing diagram of compound 7

# 3.2Biological activity

The in vitro and in vivo biological activities of the title compound were evaluated. The in vitro bioassay results showed that compound 7can effectively protect PC12 cels against Glu-induced neuronal injury. From Table 3, it was found that cell protection at three test concentrations (O.1,1.0, $1 0 ~ \mu \mathbf { M } _ { \cdot }$ ）was $3 5 . 2 8 \%$ ， $3 0 . 6 5 \%$ and $2 8 . 9 3 \%$ ,respectively. Remarkably, compound 7 showed good neuroprotective activity for all three test concentrations (protection $> 2 0 \%$ ). Compound 7 was observed to have the highest protection at the lowest concentrations of $0 . 1 \mu \mathrm { M }$ and exhibited better neuroprotection than Edaravone at the concentration of $0 . 1 \mu \mathrm { M }$ In addition,compared with Nimodipine,the title compound 7 significantly prolonged the survival time of mice subjected to acute cerebral ischemia and decrease the mortality rate at all doses $( 5 0 { \sim } 4 0 0 ~ \mathrm { m g / k g ) }$ tested in vivo (Table 4). Compound 7 exhibits effective neuroprotection and could be a lead compound for further discovery of neuroprotective agents for treating cerebral ischemic stroke.

Table 3. Neuroprotective Effects of Compound 7against   

<html><body><table><tr><td colspan="4">Glu-induced Neurotoxicity in PC12 Cells</td></tr><tr><td rowspan="2">Compound</td><td colspan="3">Protection (%)</td></tr><tr><td>10 μmol/L</td><td>1 μmol/L</td><td>0.1 μmol/L</td></tr><tr><td>The title compound</td><td>28.93*</td><td>30.65*</td><td>35.28*</td></tr><tr><td>Edaravone (90 μmol/L)</td><td></td><td>33.0*</td><td></td></tr></table></body></html>

$^ { * } p < 0 . 0 5$ vs. glutamate-treated group

Table 4.Effects of the Title Compound 7on Survival Time of Mice Subjected to Bilateral Common Carotid ArteryLigation   

<html><body><table><tr><td rowspan="2">Compound</td><td colspan="4">Survival time (min)</td></tr><tr><td>400 mg/kg</td><td>200 mg/kg</td><td>100 mg/kg</td><td>50 mg/kg</td></tr><tr><td>Compound 7</td><td>8.48 ± 1.15*</td><td>7.23 ± 1.09*</td><td>7.16 ± 1.26*</td><td>4.36 ± 0.77*</td></tr><tr><td>NS</td><td></td><td>2.04 ± 0.61</td><td></td><td></td></tr><tr><td>Nimodipine</td><td colspan="4">3.52 ± 1.04*</td></tr></table></body></html>

\*p<0.05 vs.NS.

# REFERENCES

(1)Wang,YW;Lu,H.L;n,Y.Z;iu,G.;Chu,HW;ZhaoP.YangX.H;Zheng,T.;Fn,M;Zhou,X.Z;engJ;n,C.H Networkbasedoachtifotetialeduthatpooteeuoprotetidoepiricuteico 7, 40137.   
(2) Zhang,W.Effects of Shuxuetong injection applied in acute ischemic stroke.J.Acute Dis.2016,5,507-511.   
(3) Donnan,G.A.; Fisher,M.; Macleod,M.; Davis,S.M. Stroke.Lancet.2008,371,1612-1623.   
(4) Prabhakaran,S.;Ruff,I;Bernstein,R.A.Acute stroke intervention:asystematic review.JAMA2o1,313,1451-1462.   
(5) MoretiA.;Floocrodscol4   
(6) Zhong,Y;Xu,Y;Zng,A.X;LiX.F;Xu,ZY;LiP;Wu,esisdbiolgicaevauatiofracetaidedati neuroprotective agents. Bioorg. Med. Chem. Lett.2016,26,2526-2530.   
（7） SterkDasaZ;Ji;ljciseditachteeprsofooasai Tetrahedron 2012,68,2155-2160.   
(8） Sheldrick, G.M. SHELXL97 and SHELXS97. University of Gottingen: Gottingen,Germany 1997.   
(9) Ma,S.W;Li.XH.Y;WgLY;CnLY;gJ;Zao,;gXoteiefigoeoat induced cytotoxicity in PC12 cells via inhibition of ROS generation and $\mathrm { C a } ^ { 2 + }$ influx.Neuro.Toxicology 2012,33,59-69.   
(10）WangCKe and apoptosis in differentiated PC12 cells.Naunyn-Schmied Arch.Pharmacol.2010,381,73-82.   
(1）Zhang,YY;Wag,XY;WagXuZH;uZ;;CuXP;Qu.F;Z.H;Protevecfro Scutellaria baicalensis Georgi on cerebral ischemia injury.J.Ethnopharmacol.2oo6,1O8,355-360.   
(2）YaaUl induced byacute transientand long-termbilateralcommoncarotidocclusion inrats.Pharmacol.Res.2o04,49,143-150.   
(13）Mosaidehalai 1983, 65, 55-63.   
(14）Terauchia;jaaeee.oidi effects of serofendic acid analogues. Bioorg. Med. Chem.Lett.2006,16,5080-5083.   
(15）Kong,D.L;g;WuLY;WangX.H;SiZ.F;Wu,S.;WangX;i.Stesisrctureadantiicoliif 9,9-dimethyl-9,-ydrospiobenoaante-2,3-doline]-2'(8H)-ioe.Chn.J.Strut.Ce.,5,484.   
(16）ZoY piperazin-1-yl)-methyl)benzoate.Chin.J Strut. Chem.2014,33,1096-1101.

# Synthesis, Crystal Structure and Biological Activity of1-(4-(4-Ethoxybenzyl)piperazin-1-yl)-2-(2-methylphenoxy)ethanone

LIXiao-Feng(李小凤） CHEN Xiao-Hong(陈晓宏） ZHONG Yan(仲 琰)XU Yi(许 逸）LIPing(李 萍）WUBin(吴 斌)

![](images/1648d51f553b11b1d19c571483e677a32d8b69227434ca51dc6581977a55707c.jpg)

The synthesis,crystal structure and neuroprotective activity of a new phenoxyacetyl benzylpiperazine derivative are reported.